Mechanisms and clinical applications of palmitoylethanolamide (PEA) in the treatment of neuropathic pain
ReviewHumans
- Design
- Review
- Subjects
- Narrative review
- Dose used in the study
- Not applicable
- Duration
- Not applicable
- What was measured
- Mechanisms (PPAR-alpha, mast cells, microglia, endocannabinoid interactions), pharmacokinetics and combination use in neurodegenerative disease models
What the authors reported
Experimental evidence, the authors say, shows palmitoylethanolamide reduces pain and inflammation, partly by acting on PPAR-alpha to reduce mast cell degranulation and microglial activation, and lowers the need for higher doses of other drugs. The review also covers its use alongside other therapies in models of multiple sclerosis, Parkinson's disease and Alzheimer's disease.
Limits of this study
A narrative review by authors outside the main Italian groups, with no pooled analysis. Its clinical claims rest on the trials already listed on this site. Authors declare no conflicts.
Source
PubMed 39714723 · doi:10.1007/s10787-024-01623-8
Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.